better than that- it saves the 450k -550 k of legal fees cvv has been paying per year last 1.5 yrs for both cases bottom line will now ramp... as well as top line - was a 7 mm claim- sure they got paid something up front- call this a WIN - we go higher . net income last qtr was arnd 1.3 mm with 250 legal fees .. here we go- buckle up
technicals are much better- Martin at the conference pitching CGEN along with Gilder.. 2 guys ahead of their time .. true dreamers . who knows ..... my bet next stop is 8 handle -- trade sideways before the news in the fall... just sayin.
drinks, patting on the back... who knows .. but.. i know last 30 mins of trading .. i "think" bottom may be in.. glad i sold some higher and I bought before the scramble in... still LONG and in some significant pain last 4 pts.. BUT .. if they have the secret novel sauce and there is a short term deal disclosed .... which i am confident- then technically the charts say we go to low 7's before June 8th.. I .. will be there - and - think i will be the tallest one on the floor- been a fun ride - more to come i am sure -
interesting-US Fed News Service, Including US State News
Apr 7, 2015
US Patent Issued to Compugen on April 7 for "Compositions and methods for treatment of drug resistant multiple myeloma" (American, Israeli Inventors)
ALEXANDRIA, Va., April 7 -- United States Patent no. 8,999,335, issued on April 7, was assigned to Compugen Ltd. (Tel Aviv, Israel).
"Compositions and methods for treatment of drug resistant multiple myeloma" was invented by Gad S. Cojocaru (Ramat HaSharon, Israel), Haiming Chen (West Hillls, Calif.) and James Berenson (Beverly Hills, Calif.).
According to the abstract* released by the U.
S. Patent & Trademark Office: "This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof."
The patent was filed on Sept. 16, 2011, under Application No. 13/821,176.
*For further information, including images, charts and tables, please visit:
glad to see 2014 behind CVV - 6.7 mm dollars spent on Taiwan Glass..!! thats around $1.10 PER SHARE of earnings.. the way i see it.. if there is 10-20% growth this year , and we are at All time high bookings revenues etc.. will be 16 to 18 mm in gross profit before SGA - thats $2.50 to $3.0 bucks a share gross profit- THEN lets say 7 mm in SGA for 2015 ( recall 1.8 mm was for legal fees on 2014!! AND the 4.95 settlelment .. 6.7mm GONE) - SO - say CVV makes 9-10 mm in net income for 2015 thats 1.50 per share at say a 14 multiple ( S&P at 17 for 2019 numbers not 2015! ) you get to 21 bucks per share .. simple math NOT even looking beyond 2015 ... this will go HIGHER
3.5 mm +9% interest for the last 4 yrs or so gets u too 4.9mm .. painful- But, its now behind them and no more attys fees for this going forward.. it was a waste of time and money .. mgmt cut losses and moved on- best thing i have seen out of them to date... this other Arbitration case is not filed in court because the plaintiff either cant pay to hire a real Lawyer or the firms thinks this case has no merit , the havehired this forensic acctg firm on their behalf to file in this arbitration setting .. small claims court city..also, it was for a solar film company that i think went bankrupt.. no much merit in this one..
70k shares traded is 35 k shares sold ... 290k of value trading today ... most of the prints are 100 share algo hits and lifts , clearly hits - do NOT read anything into this tape.. i do hear good things and questions will be answered on the cc ... u oldtimers have to relax and let the lemmings have their day in the sun.. btw.. last i recall we did hear from Bayer .. october with 2nd milestone .. its been less than 90 days .. really? next post here will be after the call .. bananabra - weber !!!
which of course leads me to the last points .. we will be more correlated with the IBB in days of NO news and we have support at 8.80 area- well above the 200 day Moving average - so IF any news hits- our recent Basing will pop us into SPACE -
December 15 Nasdaq mentioned CGEN added to Biotech Index.. to be honest - I didnt think much about it- until NOW - Blackrock Filed Several Days ago Holding of around 565,000 shs on CGEN...on December 19th we had HUGE volume - most of it going through at 8.83 at the close .., Clearly Blackrock was BUYING that day .. we all know the name of the index ... IBB - its massive - i didnt think it was going into to that one AND I did not think it would be 565,000 shs .. and it make sense now that our SHORT interest ROSE 500k since December 15th to Jan 15th to over 2 Million shares !! .. we now know .. 600k shares shorts @ 8.83 unless they covered during the last few days which volume doesnt coincide with ... - Bananabra- my weber grill is still burning !!
Leonard sold his 20k shares at 15 and change from 1/5 to 1/8 .. he is done selling for now- today, he wasnt selling and we ripped higher .. nice chart.
Bayer and Cgen are scheduled for Updates twice a year .. ( dates are mentioned in the redacted agmt which was posted) ending 6/30 and 12/31 .. 1st milestone right after 6/30 ..meeting then 2nd in Oct of 2014.. i have been told they are in constant communication on the process w/Bayer and a date for a meeting may not result in an announcement. All immunotherapy stocks are up.. CGEN too- wind at our backs .. maybe something in the next few weeks.. who knows.. technically, chart looks good- we have based , filled in the Gap, and now we can launch into Space - buckle UP.
this week conf calls between bayer and cgen to kick the yr off right?? hmmmm- stock sure acts like it- banabra- the stuff still in the weber grill....
When ur on the Scientific Board your compensation is CGEN equity.. Just like a director - etc- similar to our Johns Hopkins deal.. we have 2 OTHER Scientific board members on the John Hopkins Staff and they have persuaded others there that CGEN has something worth teaming up on.. its is full of conflicts - but its the way research is done .. is what it is.. ALSO ,, ding ding... Jan 1 .. thoughts we would be near 9 .. next UP - Bayer review with Compugen ..3rd milestone payment.. next stop clinicals ????
maybe there was a reason for cnbc on during my drive .. heard is oil pitches etc.. then the mention of the 2 names i have been long a very long time and trading with large positions .. almost had to pull over from choking on my steak and cheese.. u cant make this stuff up.. I think i speak to his smart friends 2x a week...
i dont know this Mark Fisher.....i did however hear this on the CNBC radio during lunchtime while out of the office.. he mentioned CERS - which I am long and have been for some time.. and then Compugen.. i guess Mark speaks to the same guys I do.... nice - we are near 9 now .. higher in MKt cap vs last year at this time with lots behind us.. milestones.. 110 mm in cash.. i figured we get here before yr end.. may have a push to 10 before yr end.. recall FPRX .. i dont own that one but if that company with Nothing Novel is outperforming on 1 deal .. can only fathom where we will be next year at this time.. good luck